PARP inhibitors enhance response to immunotherapy by promoting neoantigen release, increasing tumor mutational burden and increasing the expression of immune checkpoint regulators such as PD-L1 and CTLA-4 [38]; while promising results have been reported in solid tumors [38], further research in hematologic malignancies may also be relevant. The gene discussed is CTLA4; the disease is neoplasm.